Dimiter “Mitko” Dimitrov, PhD, has recently been named one of 10 “Science Superheroes” in leading the U.S. COVID-19 response by MediFind. Dr. Dimitrov’s laboratory discovered potent, neutralizing monoclonal antibodies to SARS-CoV-2 that received international recognition and were reported in Cell, PNAS, and mAbs.

Dr. Dimitrov was recruited to join the Department of Medicine, Division of Infectious Diseases, University of Pittsburgh from the National Institutes of Health/National Cancer Institute’s (NIH/NCI) Center for Cancer Research in 2017. He was appointed to the rank of Professor of Medicine with tenure in 2020. As Director for the Center for Antibody Therapeutics (CAT), he is responsible for the development and oversight of the Center. His work focuses on identifying new monoclonal antibodies (mAbs) as candidate therapeutics using phage and yeast display as well as to develop novel methods for antibody engineering, and generation of antibody-based candidate therapeutics including antibody drug conjugates (ADCs), chimeric antigen receptors (CARs), bispecific and multispecific antibodies, antibody-based fusion proteins, engineered antibody domains (eAds), and full size antibodies as immunoglobulin G1 (IgG1s). Under his supervision, the CAT team has identified hundreds of new mAbs and generated many antibody-based candidate therapeutics. Several of the mAbs in IgG1 and CAR formats are in clinical trials and one has been approved for compassionate use.

Dr. Dimitrov is an extraordinarily creative and gifted scientist who has applied his vast knowledge to the clinically important issues, including potentially effective therapeutics against virus infection and cancer. He is recognized worldwide for his expertise in molecular engineering and antibody therapeutics. Dr. Dimitrov serves as Editor-in Chief of the journal Antibodies. He has a remarkable record of achievement as a translational scientist, collaborator and mentor.